Stock Events

Stock Events

Recursion Pharmaceuticals 

$4.16
1143
-$0.03-0.72% Today

Statistics

Day High
4.35
Day Low
4.16
52W High
10.87
52W Low
3.85
Volume
19,221,405
Avg. Volume
25,166,650
Mkt Cap
2.14B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.53
-0.45
-0.38
-0.3
Expected EPS
-0.301429
Actual EPS
N/A

Financials

-788.02%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
117.68MRevenue
-927.32MNet Income

Analyst Ratings

$9.50Average Price Target
The highest estimate is 11.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RXRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Schwab U.S. Broad Market
SCHB
Mkt Cap0
Schrodinger operates in computational drug discovery, directly competing with Recursion's AI-driven drug discovery platform.
Exact Sciences
EXAS
Mkt Cap12.25B
Exact Sciences focuses on cancer detection and precision medicine, areas where Recursion Pharmaceuticals also aims to innovate.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides genomic sequencing solutions, competing in the broader market of personalized medicine that Recursion targets.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a field that intersects with Recursion's work in genetic-driven drug discovery.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on gene editing, competing with Recursion's efforts in leveraging genetics for drug discovery.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another gene editing company, indicating direct competition in the innovative treatment space with Recursion.
Twist Bioscience
TWST
Mkt Cap1.99B
Twist Bioscience synthesizes DNA, competing in the biotech space by enabling research that could overlap with Recursion's drug discovery efforts.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers sequencing solutions, indirectly competing by providing essential technology for genetic research like Recursion's.
Bionano Genomics
BNGO
Mkt Cap17.42M
Bionano Genomics focuses on genomic analysis, competing in the genomics space that supports Recursion's drug discovery process.

About

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Show more...
CEO
Dr. Christopher C. Gibson Ph.D.
Employees
800
Country
US
ISIN
US75629V1044

Listings

MX
MX
RXRX.MX
XNAS
US
RXRX
BOATS
BOATS
RXRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Recursion Pharmaceuticals stock price today?▼
The current price of RXRX is $4.16 USD — it has decreased by -0.72% in the past 24 hours. Watch Recursion Pharmaceuticals stock price performance more closely on the chart.
What is Recursion Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Recursion Pharmaceuticals stocks are traded under the ticker RXRX.
Is Recursion Pharmaceuticals stock price growing?▼
RXRX stock has fallen by -9.8% compared to the previous week, the month change is a -1.43% fall, over the last year Recursion Pharmaceuticals has showed a -42.82% decrease.
What is Recursion Pharmaceuticals market cap?▼
Today Recursion Pharmaceuticals has the market capitalization of 2.14B
When is the next Recursion Pharmaceuticals earnings date?▼
Recursion Pharmaceuticals is going to release the next earnings report on March 04, 2026.
What were Recursion Pharmaceuticals earnings last quarter?▼
RXRX earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.38 USD resulting in a +4.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Recursion Pharmaceuticals revenue for the last year?▼
Recursion Pharmaceuticals revenue for the last year amounts to 117.68M USD.
What is Recursion Pharmaceuticals net income for the last year?▼
RXRX net income for the last year is -927.32M USD.
How many employees does Recursion Pharmaceuticals have?▼
As of February 02, 2026, the company has 800 employees.
In which sector is Recursion Pharmaceuticals located?▼
Recursion Pharmaceuticals operates in the Health Care sector.
When did Recursion Pharmaceuticals complete a stock split?▼
Recursion Pharmaceuticals has not had any recent stock splits.
Where is Recursion Pharmaceuticals headquartered?▼
Recursion Pharmaceuticals is headquartered in Salt Lake City, US.